Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122679 | 0.83 | THRB (0.45) | THRBHPGDTSHRTHRATGM2 | |
| SCHEMBL14088490 | 0.82 | KMT2A (0.36) | THRBHPGDTSHRLMNA | |
| SCHEMBL2604672 | 0.81 | ELANE (0.43) | TSHRESR1ESR2ACHE | |
| SCHEMBL5961822 | 0.80 | KMT2A (0.34) | THRBHPGDTSHRLMNAL3MBTL1 | |
| SCHEMBL2606299 | 0.80 | THRB (0.41) | THRBHPGDTSHRTHRALMNA | |
| SCHEMBL14088468 | 0.79 | THRB (0.44) | THRBHPGDTSHRESR1ESR2 | |
| SCHEMBL14088473 | 0.78 | THRB (0.43) | THRBHPGDTSHR | |
| SCHEMBL2604705 | 0.74 | THRB (0.45) | THRBLMNAPTGS1 | |
| SCHEMBL11253852 | 0.74 | THRB (0.45) | THRBHPGDTSHRESR1ESR2 | |
| SCHEMBL11225929 | 0.73 | THRB (0.47) | THRBHPGDTHRATGM2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394468-B2 | Polymerizable compound and liquid crystal composition including it | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8394468-B2 | Polymerizable compound and liquid crystal composition including it | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | KLK3, PDE7A, FZD7 | THRB 4883/4885HPGD 1341/4885TSHR 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.